KR20230031242A - 골수증식성 신생물의 치료를 위한 병용 요법 - Google Patents

골수증식성 신생물의 치료를 위한 병용 요법 Download PDF

Info

Publication number
KR20230031242A
KR20230031242A KR1020227046429A KR20227046429A KR20230031242A KR 20230031242 A KR20230031242 A KR 20230031242A KR 1020227046429 A KR1020227046429 A KR 1020227046429A KR 20227046429 A KR20227046429 A KR 20227046429A KR 20230031242 A KR20230031242 A KR 20230031242A
Authority
KR
South Korea
Prior art keywords
pharmaceutically acceptable
acceptable salt
day
pyrrolo
methylsulfonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227046429A
Other languages
English (en)
Korean (ko)
Inventor
매튜 스터브즈
필립 씨. 류
Original Assignee
인사이트 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 인사이트 코포레이션 filed Critical 인사이트 코포레이션
Publication of KR20230031242A publication Critical patent/KR20230031242A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020227046429A 2020-06-03 2020-09-14 골수증식성 신생물의 치료를 위한 병용 요법 Pending KR20230031242A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063034214P 2020-06-03 2020-06-03
US63/034,214 2020-06-03
PCT/US2020/050753 WO2021247064A1 (en) 2020-06-03 2020-09-14 Combination of ruxolitinib with incb057643 for treatment of myeloproliferative neoplasms

Publications (1)

Publication Number Publication Date
KR20230031242A true KR20230031242A (ko) 2023-03-07

Family

ID=72659928

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227046429A Pending KR20230031242A (ko) 2020-06-03 2020-09-14 골수증식성 신생물의 치료를 위한 병용 요법

Country Status (23)

Country Link
EP (2) EP4161528B1 (https=)
JP (2) JP7669396B2 (https=)
KR (1) KR20230031242A (https=)
CN (1) CN115835868A (https=)
AU (1) AU2020451061A1 (https=)
CA (1) CA3184633A1 (https=)
CL (1) CL2022003409A1 (https=)
DK (1) DK4161528T3 (https=)
ES (1) ES3058891T3 (https=)
FI (1) FI4161528T3 (https=)
HR (1) HRP20251457T1 (https=)
IL (1) IL298200A (https=)
LT (1) LT4161528T (https=)
MA (1) MA59868B1 (https=)
MD (1) MD4161528T2 (https=)
MX (1) MX2022015220A (https=)
PH (1) PH12022553276A1 (https=)
PL (1) PL4161528T3 (https=)
PT (1) PT4161528T (https=)
RS (1) RS67440B1 (https=)
SI (1) SI4161528T1 (https=)
SM (1) SMT202600021T1 (https=)
WO (1) WO2021247064A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2023009858A (es) * 2021-02-25 2023-09-12 Impact Biomedicines Inc Uso de inhibidores de proteina de bromodominio y motivo extraterminal (bet) solo o en combinacion con fedratinib o ruxolitinib como tratamiento para una malignidad hematologica tal como la mielofibrosis.
WO2024039883A2 (en) * 2022-08-19 2024-02-22 Translational Drug Development Llc Compositions and methods to treat myeloproliferative disorders and myeloproliferative neoplasms
AU2024306742A1 (en) * 2023-06-28 2025-12-04 Active Biotech Ab Quinoline carboxamides for use in the treatment of mpn

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100786927B1 (ko) 2000-06-28 2007-12-17 스미스클라인비이참피이엘시이 습식 분쇄방법
SG10202003901UA (en) 2005-12-13 2020-05-28 Incyte Holdings Corp Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
KR20150036210A (ko) 2007-06-13 2015-04-07 인사이트 코포레이션 야누스 키나제 억제제（Ｒ）―３―（４―（７Ｈ―피롤로［２，３－ｄ］피리미딘―4―일）―1Ｈ―피라졸―1―일）―３―사이클로펜틸프로판니트릴의 염
PL3134403T3 (pl) * 2014-04-23 2020-07-13 Incyte Corporation 1H-pirolo[2,3-c]pirydyn-7(6H)-ony i pirazolo[3,4-c]pirydyn-7(6H)-ony jako inhibitory białek BET
CA3028689A1 (en) 2016-06-20 2017-12-28 Incyte Corporation Crystalline solid forms of a bet inhibitor

Also Published As

Publication number Publication date
IL298200A (en) 2023-01-01
LT4161528T (lt) 2026-02-10
SI4161528T1 (sl) 2026-01-30
EP4691563A2 (en) 2026-02-11
JP2023529365A (ja) 2023-07-10
PH12022553276A1 (en) 2024-02-19
EP4161528A1 (en) 2023-04-12
JP7669396B2 (ja) 2025-04-28
CN115835868A (zh) 2023-03-21
FI4161528T3 (fi) 2025-12-12
MX2022015220A (es) 2023-03-08
WO2021247064A1 (en) 2021-12-09
RS67440B1 (sr) 2025-12-31
DK4161528T3 (da) 2025-11-24
HRP20251457T1 (hr) 2026-01-02
PT4161528T (pt) 2026-01-23
SMT202600021T1 (it) 2026-03-09
CL2022003409A1 (es) 2023-05-26
ES3058891T3 (en) 2026-03-13
AU2020451061A1 (en) 2022-12-15
CA3184633A1 (en) 2021-12-09
EP4691563A3 (en) 2026-04-01
JP2025111539A (ja) 2025-07-30
MD4161528T2 (ro) 2026-03-31
PL4161528T3 (pl) 2026-03-16
MA59868B1 (fr) 2025-11-28
EP4161528B1 (en) 2025-11-05

Similar Documents

Publication Publication Date Title
EP3849558B1 (en) Thiocarbamate derivatives as a2a inhibitors, pharmaceutical composition thereof and combinations with anticancer agents
JP2025111539A (ja) 骨髄増殖性腫瘍の治療のための、ルキソリチニブとｉｎｃｂ０５７６４３との組合わせ
CN116096704A (zh) 用于治疗癌症的组合疗法
CN110913861B (zh) G1t38的形态学形式及其制造方法
TWI688387B (zh) 二氫槲皮素或其醫藥上可接受之鹽、或含有彼之組合物的醫藥用途
US12440495B2 (en) Combination therapy for treatment of myeloproliferative neoplasms
KR20190130644A (ko) 항암 조합 요법
CN118201615A (zh) 喹唑啉酮化合物用于治疗癌症的新用途
US11419862B2 (en) Quinoline derivative for treatment of nasopharyngeal carcinoma
CN119403808A (zh) 用于医学治疗的细胞周期蛋白依赖性激酶2抑制剂
KR20240122783A (ko) Fgfr 저해제 및 kras 저해제를 포함하는 병용 요법
CN113412262A (zh) 包含杂环蛋白激酶抑制剂的制剂
US20230165863A1 (en) Methods and formulations for administration of thiocarbamate deriviatives a2a inhibitors
CA2975116C (en) Crystalline c21h22c12n4o2 malonate
CN115038447A (zh) 用于治疗癌症的组合疗法
EP4197554A1 (en) Combined medication for treating soft tissue sarcoma
EP4736872A1 (en) Treatment method and use of pharmaceutical combination containing conjugate
WO2025094990A1 (en) Medicament for treating cancer comprising optically active azabicyclo ring derivative
HK40112852A (zh) 癌的治疗或预防用药物
EP4736884A1 (en) Treatment combination, and use thereof and treatment method
JP2025512921A (ja) （１９ｒ）－５－クロロ－３－エチル－１６－フルオロ－１０，１９－ジメチル－２０－オキサ－３，４，１０，１１，２３－ペンタアザペンタシクロ［１９．３．１．０２，６．０８，１２．０１３，１８］ペンタコサ－１（２４），２（６），４，８，１１，１３，１５，１７，２１（２５），２２－デカエン－２２－アミンを使用して固形腫瘍の治療する方法
CN112294814A (zh) 用于治疗胶质母细胞瘤的喹啉衍生物

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000